Everything below concerns IGF-1 marker. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
The effect of a mutation on protein sequence depends in part on where in the genome it occurs, especially whether it is in a coding or non-coding region. Mutations in the non-coding regulatory sequences of a gene, such as promoters, enhancers, and silencers, can alter levels of gene expression, but are less likely to alter the protein sequence. Mutations within introns and in regions with no known biological function (e.g. pseudogenes, retrotransposons) are generally neutral, having no effect on phenotype – though intron mutations could alter the protein product if they affect mRNA splicing. Mutations that occur in coding regions of the genome are more likely to alter the protein product, and can be categorized by their effect on amino acid sequence:
This caused the "most monumental nonnuclear explosion and fire ever seen from space." However, the Soviet Union did not blame the United States for the attack. In 2009, president Barack Obama declared America's digital infrastructure to be a "strategic national asset," and in May 2010 the Pentagon set up its new U.S. Cyber Command (USCYBERCOM), headed by General Keith B. Alexander, director of the National Security Agency (NSA), to defend American military networks and attack other countries' systems. The EU has set up ENISA (European Union Agency for Network and Information Security) which is headed by Prof. Udo Helmbrecht and there are now further plans to significantly expand ENISA's capabilities. The United Kingdom has also set up a cyber-security and "operations centre" based in Government Communications Headquarters (GCHQ), the British equivalent of the NSA. In the U.S. however, Cyber Command is only set up to protect the military, whereas the government and corporate infrastructures are primarily the responsibility respectively of the Department of Homeland Security and private companies. On 19 June 2010, United States Senator Joe Lieberman (I-CT) introduced a bill called "Protecting Cyberspace as a National Asset Act of 2010", which he co-wrote with Senator Susan Collins (R-ME) and Senator Thomas Carper (D-DE). If signed into law, this controversial bill, which the American media dubbed the "Kill switch bill", would grant the president emergency powers over parts of the Internet.
== Epidemiology == An estimate of in the order of 1000 dive injuries per year occur in the United States and Canada. Many of these involve barotrauma, with nearly 50% of reported injuries involving middle ear barotrauma. Diving injuries tend to correlate with trait anxiety and a tendency to panic, lack of experience, advancing age and reduction in fitness, alcohol usage, obesity, asthma, chronic sinusitis and otitis.
The crab is defined as the intensity of X-rays emitted from the Crab Nebula at a given photon energy up to 30 kiloelectronvolts. The Crab Nebula is often used for calibration of X-ray telescopes. For measuring the X-ray intensity of a less energetic source, the milliCrab (mCrab) may be used. One crab is approximately 24 pW/m2.
Sources: en.wikipedia.org
In November 1989, protestors in Berlin began taking down the Berlin Wall, which became a symbol of the collapse of the Iron Curtain, with most of Eastern Europe declaring independence and moving to hold democratic elections by 1991.
The percentage for terrible governance fell from 35% to 32%, and those who rated governance as regular rose from 22% to 25%. Between 10 and 14 August, the Genial/Quaest institute carried out its fourth survey on Lula's and his government's performance, interviewing 2,029 voters, and the results were that 42% rated the Lula government positively, while 29% classified it as regular and 24% as negative. Those who did not know or did not respond accounted for 5%. Another Ipec survey was conducted between 1 and 5 September with 2,000 voters responding in 127 municipalities, all aged over 16. Respondents who said the government was excellent or good accounted for 40% (3% higher compared with June of that year). For those who still considered it a regular government, the figure remained 32%, and those who said the government was terrible or bad accounted for 25% (3% lower). The same percentage of 3% applied to those who did not know how to rate it. The survey also showed that 56% of Brazilians approve of Lula's way of governing the country, while 39% reject it and 6% did not respond. In a Febraban/Ipespe survey released in September 2023, the popularity of the Lula government increased by 4 percentage points, reaching 55%. Disapproval, meanwhile, fell by two percentage points, to 38%. Also, 59% of Brazilians said the country would improve by the end of the year, as opposed to 18% who were pessimistic.
The two substrates of this enzyme are 4-phospho-D-erythronic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (R)-3-hydroxy-2-oxo-4-phosphonooxybutanoic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 4-phospho-D-erythronate:NAD+ 2-oxidoreductase. Other names in common use include PdxB, PdxB 4PE dehydrogenase, and 4-O-phosphoerythronate dehydrogenase. This enzyme participates in vitamin B6 metabolism.
== Other media == A Borderlands film was released by Gearbox and Lionsgate in 2024, with Eli Roth as director. The film received negative reviews from critics and poor reception from fans. In April 2020, Gearbox announced it was developing a television series based on its Brothers in Arms series.
Crustacean hyperglycaemic hormone (CHH). CHH is primarily involved in blood sugar regulation, but also plays a role in the control of moulting and reproduction. Moult-inhibiting hormone (MIH). MIH inhibits Y-organs where moulting hormone (ecdysteroid) is secreted. A moulting cycle is initiated when MIH secretion diminishes or stops. Gonad-inhibiting hormone (GIH), also known as vitellogenesis-inhibiting hormone (VIH) because of its role in inhibiting vitellogenesis in female animals. Mandibular organ-inhibiting hormone (MOIH). MOIH represses the synthesis of methyl farnesoate, the precursor of insect juvenile hormone III in the mandibular organ. Ion transport peptide (ITP) from locust. ITP stimulates salt and water reabsorption and inhibits acid secretion in the ileum of the locust. Caenorhabditis elegans uncharacterised protein ZC168.2. These neurohormones are peptides of 70 to 80 amino acid residues which are processed from larger precursors. They contain six conserved cysteines that are involved in disulfide bonds.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.